Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
HOUSTON, March 09, 2017 -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, March 14, 2017 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2016, and to provide a business overview.
To access the live conference call, please call (844) 815-4963 (domestic) or (210) 229-8838 (international) at least five minutes prior to the start time, and refer to conference ID 86497369. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company focused on developing therapeutic products utilizing DNAbilize™, its proprietary liposomal delivery and antisense technology, to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, liposomal Grb2 antisense), is in a Phase II study for blood cancers and in preclinical studies for solid tumors. Bio-Path’s second drug candidate, also a liposomal antisense drug, is ready for the clinic where it will be evaluated in lymphoma and solid tumors.
For more information, please visit the Company's website at http://www.biopathholdings.com.
Contact Information: Investors Will O’Connor Stern Investor Relations 212-362-1200 [email protected] Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369
